Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 18Sarcoma 9Gastrointestinal 7Myeloid 6Lymphoid 6Genitourinary 6NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 15Thyroid Neoplasms 3Gastro-enteropancreatic neuroendocrine tumor 3Brain Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Testicular Neoplasms 2Prostatic Neoplasms 2Paraganglioma 2Neuroblastoma 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Adrenal Gland Neoplasms 2Adenoma, Islet Cell 2von Hippel-Lindau Disease 1Vaginal Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1Thymus Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Solitary Fibrous Tumors 1Skin Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Pheochromocytoma 1Penile Neoplasms 1

Interventions

gallium Ga 68 dotatate 2pentetreotide 1olaparib 1lutetium Lu 177 dotatate 1arginyllysine 1Whole Body Imaging 1Magnetic Resonance Spectroscopy 1Amino Acids 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Medulloblastoma × Magnetic Resonance Spectroscopy × NET × Clear all
NCT01869725 2021-09-22

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

University of Iowa

Phase 2 Completed
68 enrolled 8 charts
CNSEndocrineNET

Medulloblastoma, Neuroblastoma, Somatostatinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡